Serpin peptidase inhibitor family G1 (SERPING1) was identified as a novel marker in diagnosis and prognostic prediction in prostate cancer, indicating a strong correlation between decreased expression and the poor prognosis [16]. Here, SERPING1 is linked to prostate cancer.